Enteral Fish Oil is Superior to Ursodeoxycholic Acid (UDCA) and Placebo for the Treatment of Cholestasis in Infants
| Status: | Withdrawn |
|---|---|
| Conditions: | Gastrointestinal |
| Therapuetic Areas: | Gastroenterology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 6/22/2016 |
| Start Date: | June 2016 |
| End Date: | June 2016 |
Enteral Fish Oil is Superior to Ursodeoxycholic Acid (UDCA) and Placebo (?) for the Treatment of Cholestasis in Infants
To investigate the effect of enteral fish oil and UDCA on the time of cholestasis resolution
and other markers of parenteral nutrition-associated liver disease.
and other markers of parenteral nutrition-associated liver disease.
Inclusion Criteria:
Neonates admitted to the Neonatal Intensive Care Unit (NICU) at University Hospital (UH)
in San Antonio, Texas, who:
1. Are >14 days old and <24 months of age
2. Have a serum direct bilirubin of ≥2 mg/dL
3. Are receiving <3 g/k/day of Intralipid via TPN
4. Are expected to remain hospitalized for at least an additional 21 days
Exclusion Criteria:
1. Have a congenitally lethal condition (e.g. Trisomy 13)
2. Have clinically severe bleeding not able to be managed with routine measures
3. Have evidence of a viral hepatitis or primary liver disease as the etiology of their
cholestasis
4. Have other health problems such that survival is extremely unlikely even if
cholestasis improves
5. Known allergy to eggs or fish products
6. Receiving IV Fish oil
7. Phenobarbital therapy at enrollment
We found this trial at
1
site
Click here to add this to my saved trials
